Literature DB >> 16186322

Histopathological features and P-glycoprotein expression in retinoblastoma.

João Pessoa Souza Filho1, Zelia Maria S Correa, Alexandre N Odashiro, Anamaria Baptista Coutinho, Maria Cristina Martins, Clélia Maria Erwenne, Miguel N Burnier.   

Abstract

PURPOSE: To investigate the expression of P-glycoprotein (P-gp) in retinoblastoma specimens enucleated as a primary treatment or after conservative treatment and to correlate this expression with histopathological tumor features.
METHODS: Retrospective analysis was performed on retinoblastoma specimens obtained consecutively between 1993 and 2003 by enucleation either as primary treatment (group I) or after the failure of conservative treatment (group II). Sections from the formalin-fixed, paraffin-embedded specimens were stained with hematoxylin and eosin. Group I tumor differentiation was classified according to the percentage of Flexner-Wintersteiner rosettes. Group II tumors, categorized as viable-appearing, regressed with a well-differentiated component (WDC), and regressed. Other features, such as choroidal and optic nerve invasion, were evaluated. P-gp expression was graded semiquantitatively as negative, low, or high. Variables were statistically analyzed by chi(2) and Student's t-tests.
RESULTS: Histopathological assessment of group I revealed 65% moderately differentiated tumors, 30% well differentiated, and 5% poorly differentiated. Fifteen percent had optic nerve tumor invasion only, 20% choroidal invasion only, and 55% both choroidal and optic nerve invasion. Group II had 62.5% well-differentiated, regressed tumors; 25% had regressed tumors replaced by glial scarring; and 12.5% had tumors containing viable, poorly differentiated cells. Approximately 18% had choroidal tumor invasion only, 6.3% optic nerve tumor invasion only, and 6.3% simultaneous optic nerve and choroidal invasion. P-gp expression was observed in 60% of group I and 66.6% of group II. All P-gp-positive cases in group II had a high expression. P-gp was also expressed by 81.2% of well-differentiated tumors.
CONCLUSIONS: P-gp was expressed more frequently by well-differentiated retinoblastomas, especially those treated by chemotherapy before enucleation. This finding could be related to treatment failure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16186322     DOI: 10.1167/iovs.04-1290

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

1.  The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines.

Authors:  L R de Moura; J-C Marshall; S Di Cesare; B F Fernandes; E Antecka; M N Burnier
Journal:  Eye (Lond)       Date:  2012-11-16       Impact factor: 3.775

2.  Expression of C-kit in retinoblastoma: a potential therapeutic target.

Authors:  Robert J Barry; Letícia R de Moura; Jean-Claude Marshall; Bruno F Fernandes; Maria Eugenia Orellana; Emilia Antecka; Claudia Martins; Miguel N Burnier
Journal:  Br J Ophthalmol       Date:  2007-06-25       Impact factor: 4.638

3.  Characterization of the ATP-binding cassette transporter gene expression profile in Y79: a retinoblastoma cell line.

Authors:  Doris Hendig; Thomas Langmann; Ralf Zarbock; Gerd Schmitz; Knut Kleesiek; Christian Götting
Journal:  Mol Cell Biochem       Date:  2009-03-06       Impact factor: 3.396

4.  Expression of multidrug-resistance associated proteins in human retinoblastoma treated by primary enucleation.

Authors:  Li-Juan Tang; Li-Jun Zhou; Wen-Xin Zhang; Jian-Yan Lin; Yong-Ping Li; Hua-Sheng Yang; Ping Zhang
Journal:  Int J Ophthalmol       Date:  2018-09-18       Impact factor: 1.779

5.  An immunohistochemical analysis of P-glycoprotein in retinoblastoma.

Authors:  Sumita Sethi; Parul Saxena; Seema Kashyap; Neelam Pushker; Jasbir Kaur; Supriyo Ghose
Journal:  Oman J Ophthalmol       Date:  2012-05

6.  Correlation of Technical and Adjunctive Factors with Quantitative Tumor Reduction in Children Undergoing Selective Ophthalmic Artery Infusion Chemotherapy for Retinoblastoma.

Authors:  T Abruzzo; K Abraham; K B Karani; J I Geller; S Vadivelu; J M Racadio; B Zhang; Z M Correa
Journal:  AJNR Am J Neuroradiol       Date:  2020-12-24       Impact factor: 3.825

7.  Expression of P-glycoprotein in human retinoblastoma and its clinical significance.

Authors:  Sumita Sethi; Manzoor Ahmad Malik; Sandeep Goswami; Parul Saxena; Arpna Srivastava; Seema Kashyap; Neelam Pushker; Mandeep Singh Bajaj; Sameer Bakhshi; Jasbir Kaur
Journal:  Tumour Biol       Date:  2014-08-31

8.  Characterization of etoposide- and cisplatin-chemoresistant retinoblastoma cell lines.

Authors:  Maike Busch; David Papior; Harald Stephan; Nicole Dünker
Journal:  Oncol Rep       Date:  2017-11-16       Impact factor: 3.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.